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RESULTS  
(in greater detail than the main paper) 
From our trials database we included 47 RCTs (49 comparisons, including 108,194 participants) 
that assessed outcomes of interest to this review.  Thirty four trials (including 97,548 participants) 
assessed effects of LCn3, three (3179 participants) assessed effects of ALA, eight (4976 
participants) assessed effects of omega-6 and 9 trials (including 11,573 participants) assessed 
effects of total PUFA (Supplementary Table 1).  Several trials assessed more than one of these 
interventions, so numbers of trials and participants are not additive.  Of the 47 trials, 38 included 
participants with normal baseline cancer risk (including healthy adults and those with risk factors for 
other diseases, or existing disease including CVD, diabetes and eye diseases), 3 included 
participants with cancer risk factors (2 at high risk of breast cancer, 1 at high risk of bowel cancer) 
and 6 included participants with previously diagnosed cancer (1 postoperative breast cancer, 3 
postoperative colorectal cancer, 1 prostate cancer, one skin cancer).  Most trials provided 
supplementary capsules, but trials of omega-6 and total PUFA tended to provide dietary advice with 
or without supplementary foods, some trials provide supplementary foods (such as enriched 
margarines, nuts, and one (set in an institution) provided all food.  In four trials the intervention was 
to reduce fat intake, which also reduced PUFA, so for these trials the higher PUFA arm was the 
study control arm.  Mean trial duration was over 30 months, and most trials were conducted in 
Europe (20 trials) or North America (15 trials), five were conducted in Japan, two in Australia and/or 
New Zealand, and five were conducted over more than one continent. Seventeen of the 47 trials 
were at low summary risk of bias (Supplementary Figure 1, Supplementary Table 1).   
 
Effects of long-chain omega-3 fat on risk of any cancer 
 
Effects of LCn3 on all primary and secondary outcomes, along with sensitivity analyses and 
subgroupings are displayed in Supplementary Tables 2 and 3.  The GRADE assessment is 
shown in Supplementary Table 4.  
Meta-analysis of 27 trials (113,557 participants) reporting from 1 to 1784 cancer diagnoses 
suggested little or no effect on any cancer diagnosis (RR 1.02, 95% CI 0.98 to 1.07, I2 0%, 
Figure 1 in the main paper, high quality evidence), and this lack of effect did not alter in 
fixed effects meta-analysis, when limiting to trials at low summary risk of bias, low risk of 
compliance issues or larger trials (at least 100 randomised participants).  There was no 
suggestion of heterogeneity between trials and the funnel plot did not suggest small study 
bias (Supplementary Figure 2). Subgrouping did not suggest differences in effect by 
duration, dose, nutrients replaced by LCn3, intervention type, age, sex or baseline cancer 
risk (test for subgroup differences all p>0.05). Mean duration of included trials was 32 
months (SD 22, range 12 to 88 months) and mean dose of LCn3 was 1.7g/d (SD 1.2g/d, 
range 0.5 to 4.6g/d).  Increasing LCn3 has little or no effect on risk of diagnosis of any 
cancer (high quality evidence). 
Eighteen trials (99,336 participants) provided data on 2277 cancer deaths and meta-
analysis suggested little or no effect of increasing LCn3 (RR 0.97, 95% CI 0.90 to 1.06, I2 
0%, Figure 2 in the main paper), and the lack of effect didn’t alter in any sensitivity analysis.  
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Subgrouping did not suggest differential effects by trial duration, LCn3 dose, replacement 
for LCn3, intervention type, age, sex or baseline cancer risk.  There was no suggestion of 
heterogeneity between trials, and the funnel plot showed no sign of small study bias 
(Supplementary Figure 3). Mean duration of included trials was 43 months (SD 22, range 
12 to 88 months) and mean dose of LCn3 was 1.6g/d (SD 1.5g/d, range 0.4 to 6.0g/d). 
Increasing LCn3 probably has little or no effect on risk of cancer death (moderate quality 
evidence, downgraded once for imprecision). 
 
Effects of long-chain omega-3 fat on risk of breast cancer 
 
Meta-analysis of 12 trials (92,736 participants, 44,304 women) reporting from 1 to 246 
breast cancer diagnoses (661 diagnoses overall) suggest little or no effect of LCn3 on 
breast cancer diagnosis (RR 1.03, 95% CI 0.89 to 1.20, I2 0%, Figure 3 in the main paper), 
and this lack of effect did not alter in fixed effects meta-analysis, when limiting to trials at 
low summary risk of bias, low risk of compliance issues or larger trials (at least 100 
randomised participants).  There was no suggestion of heterogeneity between trials. 
Subgrouping did not suggest differences in effect by duration, dose, nutrients replaced by 
LCn3, intervention type, age, sex or baseline cancer risk (test for subgroup differences all 
p>0.05), however trials tended to cluster into specific subgroups rather than be spread 
evenly across subgroups, so differences would be harder to see. There was no suggestion 
of small study bias in the funnel plot (Supplementary Figure 4). Mean duration of included 
trials was 48 months (SD 25, range 12 to 88 months) and mean dose of LCn3 was 1.9g/d 
(SD 1.5g/d, range 0.6 to 4.6g/d).  Increasing LCn3 probably has little or no effect on risk of 
breast cancer diagnosis (moderate quality evidence, downgraded once for imprecision). 
Two trials (including 3322 participants, 102 women) reported breast cancer deaths, but 
each reported a single death, so there were insufficient data to assess effects 
(Supplementary Figure 5). One of the included trials is a male only study but we included 
the data in Supplementary Figure 5 as it reported a single death from breast cancer 1, men 
are not included in other breast cancer trials. Mean duration of included trials was 60 
months (SD 17, range 48 to 72 months) and mean dose of LCn3 was 0.9g/d (SD 0.5g/d, 
range 0.5 to 1.2g/d). The effect of increasing LCn3 on breast cancer deaths is unclear as 
the evidence is of very low quality (downgraded once for risk of bias, twice for imprecision). 
Lower breast density is associated with lower risk of breast cancer in women. A single trial 
(not at low summary risk of bias) of 175 women reported on breast density, suggesting a 
mean difference of 2.06cm2 (95% CI -4.68 to 8.81, Supplementary Figure 6), a change of 
less than 10% from the control group baseline of 56cm2. This did not change in fixed effects 
sensitivity analysis or retaining trials of at least 100 participants, but the single trial was lost 
in sensitivity analyses on summary risk of bias and risk from compliance problems.  The 
effect of increasing LCn3 was unclear as the evidence was of very low quality (downgraded 
once for imprecision and risk of bias, downgraded twice for indirectness). 
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Effects of long-chain omega-3 fat on prostate cancer  
 
Seven trials (63,460 participants, 38,525 men) reported on 1021 prostate cancer 
diagnoses, finding higher risk of prostate cancer in men with increased LCn3 (RR 1.10, 
95% CI 0.97 to 1.24, I2 0%, Figure 4 in the main paper).  This slight increase in prostate 
cancer risk was stable to all sensitivity analyses.  With so few trials we did not carry out 
subgrouping or assess funnel plots. However, the suggestion of harm was contradicted by 
findings on PSA (below). Mean duration of included trials was 51 months (SD 24, range 24 
to 88 months) and mean dose of LCn3 was 1.2g/d (SD 1.5g/d, range 0.4 to 4.5g/d).  
Increasing LCn3 may increase the risk of prostate cancer (low quality evidence, 
downgraded once each for imprecision and inconsistency).  
Prostate cancer deaths were reported in only two trials (5 deaths in 5616 participants, 5101 
men, Supplementary Figure 7) so effects of LCn3 on prostate cancer deaths could not be 
assessed.  The trials were of 48 and 72 months duration, doses of LCn3 were 0.5 and 
0.6g/d.  The effect of increasing LCn3 on prostate cancer death is unclear as the evidence 
is of very low quality (downgraded once for inconsistency and twice for imprecision).  
Prostate specific antigen (PSA) is a marker of prostate cancer risk, and higher PSA is 
associated with higher risk.  PSA was reported as a continuous measure in a single large 
trial of 1622 participants (at low summary risk of bias, MD -0.13ng/ml, 95% CI -0.25 to 0.01, 
Supplementary Figure 8), suggesting a fall of 25% from a baseline of 0.53ng/ml in those on 
higher LCn3. Odds of increased PSA was reported in a single trial (not at low summary risk 
of bias) of 62 participants, reporting only 12 participants with raised PSA (RR 0.47, 95% CI 
0.16 to 1.40, Supplementary Table 2), but also suggesting protective effects of LCn3 on 
PSA.   
 
Effects of ALA on risk of any cancer 
 
Effects of ALA on all primary and secondary outcomes, along with sensitivity analyses and 
subgroupings are displayed in Supplementary Tables 5 and 6.  The GRADE assessment is 
shown in Supplementary Table 4.  
Meta-analysis of 2 trials (752 participants) reported 16 cancer diagnoses and suggested 
little or no effect on risk of  cancer diagnosis (RR 0.98, 95% CI 0.38 to 2.55, I2 0%, Figure 1 
in the main paper), and this lack of effect did not alter in fixed effects meta-analysis, but no 
trials were at low summary risk of bias.  The single large trial (with >100 participants) was 
also the single trial at low risk of compliance issues and suggested a slight increase in 
cancer risk with increased ALA (RR 1.09, 95% CI 0.40 to 2.98) but with very wide 
confidence intervals. As there were only two trials we did not attempt subgrouping or a 
funnel plot.  Mean duration of included trials was 18 months (12 and 24 months), mean 
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dose of LCn3 was 4.2g/d (3.3 and 5.0g/d).  The effect of increasing ALA on diagnosis of 
any cancer is unclear as the evidence was of very low quality (downgraded once for risk of 
bias, twice for imprecision).  
Two trials (5545 participants) provided data on 123 cancer deaths and meta-analysis 
suggested little or no effect of LCn3 (RR 1.05, 95% CI 0.74 to 1.49, I2 0%, Figure 2 in the 
main paper), which didn’t alter in any sensitivity analysis.  Subgrouping and funnel plots re 
not attempted. Duration of included trials was 24 and 40 months, doses of LCn3 were 2 and 
5g/d.   Increasing ALA probably has little or no effect on risk of cancer death (moderate 
quality evidence, downgraded once for imprecision). 
 
Effects of ALA on risk of breast cancer 
 
Two trials (752 participants, 513 women) reported only 4 breast cancer diagnoses, and no 
trials reported deaths from breast cancer or breast density, so there were insufficient data 
to assess effects on breast cancer diagnoses, deaths or markers (Figure 3 in the main 
paper and Supplementary Figure 5). Duration of included trials of breast cancer diagnosis 
was 12 and 24 months, doses of LCn3 were 3.3 and 5.0g/d.  The effect of increasing ALA 
on risk of breast cancer diagnosis is unclear as the evidence is of very low quality 
(downgraded once for risk of bias, twice for imprecision),  
 
Effects of ALA on risk of prostate cancer 
 
Meta-analysis of 2 trials (5545 participants, 4010 men) reporting 46 prostate cancer 
diagnoses suggesting that increasing ALA increases risk of prostate cancer diagnosis (RR 
1.30, 95% CI 0.72 to 2.32, I2 0%, Figure 4 in the main paper).  This increase in risk was 
consistent across all sensitivity analyses, and supported by a rise in PSA with ALA (below).  
Mean duration of included trials was 32 months (24 and 40 months), mean dose of LCn3 
was 3.5g/d (2.0 and 5.0g/d).  Increasing ALA may increase the risk of prostate cancer 
diagnosis (low quality evidence, downgraded twice for imprecision). 
No trials reported deaths from prostate cancer (Supplementary Figure 7). A single large trial 
at low summary risk of bias reported increased risk of raised PSA (>4ng/ml, RR 1.13, 95% 
CI 0.86 to 1.50) and higher PSA (by 23% from baseline, MD 0.10ng/ml, 95% CI -0.03 to 
0.23, Supplementary Figure 8) in those taking more ALA.   
 
Effects of omega-6 on risk of any cancer 
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Effects of omega-6 on all primary and secondary outcomes, along with sensitivity analyses 
and subgroupings are displayed in Supplementary Tables 7 and 8.  The GRADE 
assessment is shown in Supplementary Table 9.  
Six trials (4272 participants, 262 cancer diagnoses) suggested that increasing omega-6 
increased risk of diagnosis of any cancer (RR 1.21, 95% CI 0.96 to 1.53, I2 0%, Figure 1 in 
the main paper).  The increased risk was consistent between dietary and supplemental 
interventions, and in all sensitivity analyses except when restricting to the single trial at low 
summary risk of bias.  Mean duration of the included trials was 30 months (SD 25, range 12 
to 72 months), mean dose was 10.7%E from omega-6, but varied enormously (SD 13.9, 
median 6.4%E, range 0.2 to 37.8%E from omega-6).  The effect of increasing omega-6 on 
cancer diagnosis is unclear as the evidence is of very low quality (downgraded twice for risk 
of bias, once for imprecision). 
Meta-analysis of the four trials assessing effects of omega-6 on cancer deaths was 
heterogeneous, and suggested little or no effect (RR 0.97, 95% CI 0.51 to 1.85, I2 52%, 
Figure 2 in the main paper).  However, none of the trials were at low summary risk of bias, 
and fixed effects analysis suggested in increase in risk of cancer death.  No subgrouping or 
funnel plots were run as we included few trials. Mean duration of the included trials was 37 
months (SD 12, range 24 to 48 months), mean dose was 14.0%E from omega-6, but varied 
a great deal (SD 21.0, median 2.8%E, range 1.4 to 37.8%E from omega-6).  The effect of 
omega-6 on cancer deaths is unclear as the evidence is of very low quality (downgraded 
once each for risk of bias, imprecision and inconsistency). 
 
Effects of omega-6 on risk of breast and prostate cancer 
 
Only one small trial (200 women participants, 4 breast cancer diagnoses, 12 months 
duration, 2.7%E from omega-6, Figure 3) assessed effects of omega-6 on breast cancer 
diagnosis, and none on breast cancer deaths or breast density (Supplementary Figures 5 
and 6), so there were insufficient data to assess effects. The effect of omega-6 on breast 
cancer diagnoses is unclear as the evidence is of very low quality (downgraded once for 
risk of bias, once for indirectness and twice for imprecision). 
One trial (2033 male participants, 24 months duration, 2.8% E increase in omega-6) that 
was not at low summary risk of bias reported 13 prostate cancer diagnoses (RR 2.24, 95% 
CI 0.69 to 7.26, Figure 4 in the main paper), no trials reported prostate cancer deaths or 
PSA.  The effect of omega-6 on risk of prostate cancer diagnosis is unclear as the evidence 
is of very low quality (downgraded once each for risk of bias, indirectness and imprecision). 
 
Effects of total PUFA on risk of any cancer 
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Effects of total PUFA on all primary and secondary outcomes, along with sensitivity 
analyses and subgroupings are displayed in Supplementary Tables 10 and 11.  The 
GRADE assessment is shown in Supplementary Table 12.  
Eight trials (9428 participants, 436 diagnoses) assessed effects of increasing total PUFA on 
cancer diagnosis, suggesting that increasing total PUFA increases diagnosis risk (RR 1.19, 
95% CI 0.99 to 1.42, I2 0%, Figure 1 in the main paper).  This was consistent across all 
sensitivity analysis (except when limiting to the three trials at low summary risk of bias, 
where the RR was 1.08).  The funnel plot is difficult to assess with only 8 included trials, but 
does suggest that smaller trials with higher RRs may be missing (Supplementary Figure 9).  
If such trials were added back in the RR would rise further.  Subgrouping did not suggest 
important differences between subgroups by study duration, PUFA dose (Supplementary 
Figure 10), replacement, age, sex and baseline cancer risk.  Mean duration of the included 
trials was 39 months (SD 24, range 12 to 72 months), mean dose was 9.6%E from total 
PUFA, median 3.3%E, and varied considerably (SD 13, range 0.8 to almost 38%E from 
total PUFA).  Increasing total PUFA may increase risk of diagnosis of any cancer 
(downgraded once each for risk of bias and imprecision). 
Four trials reported on cancer deaths (3407 participants, 73 deaths), suggesting that 
increasing total PUFA increases risk of death from cancer (RR 1.10, 95% CI 0.48 to 2.49, I2 
37%, Figure 2 in the main paper). This increase in risk of cancer death was consistent 
across all sensitivity analyses.  We did not carry out subgrouping or funnel plots as there 
were only four trials. Mean duration of the included trials was 39 months (SD 27, range 12 
to 72 months), mean dose was 13%E from total PUFA, median 7%E, and varied 
considerably (SD 17, range 0.8 to almost 38%E from total PUFA).  Increasing total PUFA 
may increase the risk of cancer death (downgraded twice for imprecision). 
 
Effects of total PUFA on risk of breast cancer 
 
Meta-analysis of two trials (5198 female participants, 79 diagnoses) suggested that 
increasing total PUFA increases risk of breast cancer diagnosis, but with very wide 
confidence intervals (RR 1.11, 95% CI 0.71 to 1.73, I2 0%, Figure 3 in the main paper).  
However, this was not supported in sensitivity analysis limiting to the single trial at low 
summary risk of bias, and neither trial was at low risk of compliance problems. Duration of 
both trials was 60 months and the dose was 2%E from total PUFA in one trial, unclear in 
the other.   The effect of increasing total PUFA on risk of breast cancer diagnosis is unclear 
as the evidence is of very low quality (downgraded once for risk of bias and twice for 
imprecision). 
No trials reported breast cancer deaths or breast density (Supplementary Figures 5 & 6).  
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Effects of total PUFA on risk of prostate cancer 
 
Meta-analysis of two trials (2879 male participants, 32 diagnoses) suggested that 
increasing total PUFA increases risk of prostate cancer diagnosis, but with the small 
number of diagnoses, confidence intervals were very wide (RR 1.64, 95% CI 0.80 to 3.36, I2 
0%, Figure 4 in the main paper).  No trials were at low summary risk of bias, all other 
sensitivity analyses suggested increased prostate cancer risk with increased total PUFA. 
Duration of the included trials was 24 and 72 months, doses 3 and 11%E from total PUFA.   
The effect of increasing total PUFA on prostate cancer diagnosis is unclear as the evidence 
is of very low quality (downgraded once for risk of bias and twice for imprecision). 
No trials reported prostate cancer deaths or PSA (Supplementary Figures 7 & 8).  
 
Secondary outcomes 
 
Prostate cancer diagnoses and deaths are reported above.  Effects on body weight and 
measures of adiposity are reported in full (not just in this subset of trials assessing cancer 
outcomes) in other reviews in this series so are noted in the Supplementary Tables, but not 
discussed further here.2-4 We found no trials reporting any measure of quality of life as 
effects of increases in LCn3, ALA, omega-6 or total PUFA.   
When increasing LCn3 risks of gastrointestinal side effects (RR 1.11, 95% CI 0.89 to 1.31, 
I2 84%, including effects on nausea, reflux, diarrhoea and hospitalisation for gastrointestinal 
problems), bleeding (RR 1.09, 95% CI 0.70 to 1.70, I2 59%), and dropouts due to side 
effects (RR 1.31, 95% CI 0.98 to 1.76, I2 19%) appear increased, while risk of headache or 
migraine (RR 0.81, 95% CI 0.48 to 1.36, I2 0%), and psychiatric problems (RR 0.70, 95% CI 0.32 
to 1.54, I2 0%), appear reduced (Supplementary Figure 11).  Overall giving LCn3 appears to 
have little or no effect on risk of all side effects combined (RR 1.03, 95% CI 0.93 to 1.15, I2 
85%), or dropouts for any reason (RR 0.98, 95% CI 0.88 to 1.10, I2 33%, Supplementary 
Figures 11 and 12).  
Data on side effects and dropouts are much more limited for ALA (Supplementary Figure 
13) and omega-6 (Supplementary Figure 14, all data on side effects and dropouts shown), 
and no data were available for trials of total PUFA.   
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Supplementary Figure 1: Summary risk of bias of included comparisons by domain as assessed by 
reviewers.  
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Supplementary Figure 2.  Funnel plot for effects of LCn3 on diagnosis of any cancer.  
 
 
Supplementary Figure 3.  Funnel plot for effects of LCn3 on death from any cancer.  
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Supplementary Figure 4.  Funnel plot for effects of LCn3 on diagnosis of breast cancer.  
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Supplementary Figure 5.  Forest plot showing effects of increasing omega-3, omega-6 and total PUFA 
on deaths from breast cancer in women participants, using random-effects meta-analyses. 
 
 
Supplementary Figure 6.  Forest plot showing effects of increasing omega-3, omega-6 and total PUFA 
on breast density in cm2, using random-effects meta-analyses. 
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Supplementary Figure 7.  Forest plot showing effects of increasing omega-3, omega-6 and total PUFA 
on deaths from prostate cancer in male participants, using random-effects meta-analyses. 
 
 
Supplementary Figure 8.  Forest plot showing effects of increasing omega-3, omega-6 and total PUFA 
on prostate specific antigen (PSA, ng/ml), using random-effects meta-analyses. 
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Supplementary Figure 9.  Funnel plot for effects of total PUFA on diagnosis of any cancer.   
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Supplementary Figure 10.  Meta-analysis assessing effects of increasing total PUFA on diagnosis of 
any cancer, subgrouping by dose of PUFA (as percentage of energy intake).   
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Supplementary Figure 11.  Forest plot showing effects of increasing LCn3 on side effects using 
random-effects meta-analyses. 
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Supplementary Figure 12.  Forest plot showing effects of increasing LCn3 on dropouts using random-
effects meta-analyses. 
 
 
Supplementary Figure 13.  Forest plot showing effects of increasing ALA on side effects using 
random-effects meta-analyses. 
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Supplementary Figure 14.  Forest plot showing effects of increasing omega-6 on dropouts using 
random-effects meta-analyses. 
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Supplementary Table 1. Table of characteristics, risk of bias and references for included trials 
 
 
Trial name & 
reference 
Comparison Participants Number 
randomised 
Intervention Duration of 
intervention 
Summary 
risk of bias 
Location 
AlphaOmega – ALA 
5-8   
n3 ALA vs MUFA 60-80 year olds with 
previous MI 
 
1197 ALA 
intervention, 1236 
control 
Supplementary margarine, 20g/d 
enriched margarine incorporating 
2g/d ALA 
40 months Low The 
Netherlands 
AlphaOmega - 
EPA+DHA 5-8 
n3 EPA+DHA vs 
MUFA 
60-80 year olds with 
previous MI 
1192 EPA/DHA 
intervention, 1236 
control 
Supplementary Margarine, 20g/d 
enriched margarine incorporating 
400mg/d LCn3 (240mg/d EPA, 
160mg/d DHA) 
40 months Low The 
Netherlands 
AREDS2 2014 9-11 n3 EPA+DHA vs 
nil 
50-85 year olds at high 
risk of age-related 
macular degeneration 
2147 DHA/EPA,  
2056 placebo 
Supplement (capsule), 350 mg/d 
DHA plus 650 mg/d EPA added to 
standard AREDS supplement 
60 months Low USA
ASCEND 2018 12, 13   n3 EPA + DHA vs 
MUFA 
Patients with DM, 
without apparent 
vascular disease 
7740 intervention, 
7740 control 
Supplement (capsule), 840mg/d 
EPA+DHA (460mg/d EPA, 380mg/d 
DHA) as 1 capsule daily 
Median 7.4 
years 
Low UK
Berson 2004 14, 15 n3 DHA vs n6 LA People aged 18-55 with 
retinitis pigmentosa  
221 randomised 
overall, analysed 
105 intervention, 
103 control 
Supplement (capsule), 1.2g/d DHA 
plus 1.8g vegetable oil 
48 months Low USA
Black 1994 16, 17 Higher vs lower 
n6, higher vs 
lower PUFA 
(inverted) 
**People with non-
melanoma skin cancer 
66 intervention, 
67 control 
Dietary advice, reduce total fat to 
20%E, including omega 6 and total 
PUFA 
24 months Moderate or 
high 
USA
DART fat Burr 1989 
18-20   
n6 LA vs mixed 
fats, also higher 
vs lower PUFA 
Men recovering from MI 1018 
Intervention, 
1015 control 
dietary advice, ↑ PUFA oil & n6 
margarines vs usual dietary fats 
24 months Moderate to 
high 
UK
DART fish Burr 
1989 18-20 
n3 EPA+DHA vs 
mixed fat 
Men recovering from MI
 
1015 intervention, 
1018 intervention 
Dietary advice, advised to eat ≥2 
portions/wk of 200-400g fatty fish, if 
not possible given MaxEPA capsules, 
0.5g EPA/d 
24 months Moderate or 
high 
UK
DART2 - Burr 
2003 1 
n3 EPA+DHA vs 
nil 
Men treated for angina 1571 intervention, 
1543 control 
dietary advice, advised to eat ≥2 
portions/wk of 200-400g fatty fish, if 
not possible given MaxEPA capsules, 
0.5g EPA /d 
3-9 years Moderate or 
high 
UK
DIPP-Tokudome n3 **Patients previously 104 intervention, Advice plus supplement, reduce 24 months Moderate or Japan
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2015   EPA+DHA+ALA vs 
nil 
polypectomised for 
colorectal tumours 
101 control total fat intake, decrease n-6 PUFAs, 
increase fishy n-3 PUFAs, increase n-
3 PUFAs from perilla oil rich in ALA, 
and take 8 capsules of fish oil/day 
(96 mg/d EPA, 360 mg/d DHA) 
high
DO IT - Einvik 2010 
21, 22 
n3 DHA+EPA vs 
n6 LA 
Elderly men with long 
standing dyslipidaemia or 
hypertension 
282 intervention, 
281 control 
Supplement (capsule), 2.4g/d of 
omega 3 (0.84g/d EPA & 0.48g/d 
DHA) 
36 months Moderate or 
high 
Norway 
EPE-A Sanyal 2014 
23 
n3 EPA, low dose 
vs high dose vs 
unclear placebo 
People with non-alcoholic 
steatohepatitis or fatty 
liver disease 
86 intervention 
(high dose), 82 
intervention (low 
dose), 75 control 
Supplement (capsule), High dose 
EPA-E 2.7g/d, low dose 1.8g/d 
12 months Moderate or 
high 
USA
EPIC-1 2008 24 n3 EPA+DHA vs 
mixed fat 
Adults with quiescent 
Crohn’s disease (CDAI) 
score <150 
188 intervention, 
186 control 
Supplement (capsule), 2.2g/d EPA, 
0.8g/d DHA 
12 months Moderate or 
high 
Canada, 
Europe, 
Israel, USA 
EPIC-2 2008 24  n3 EPA+DHA vs 
mixed fat 
Adults with Crohn’s 
disease 
189 intervention, 
190 control 
Supplement (capsule), 2.2g/d EPA, 
0.8g/d DHA 
13 months Moderate or 
high 
Canada, 
Europe, 
Israel, USA 
FOSTAR 2016 25  n3 EPA+DHA vs 
low n3 
EPA+DHA+ALA 
Adults aged 40+ with 
knee osteoarthritis 
101 intervention, 
101 control 
Supplementary food (enriched 
orange juice), 4.5g/d EPA+DHA 
24 months Low Australia 
GISSI-HF 2008 26, 27 n3 EPA+DHA vs 
MUFA 
Patients with chronic 
heart failure 
3494 intervention, 
3481control 
Supplement (capsule), 866mg/d EPA, 
1039mg/d DHA, Total Omega-3 Fat: 
1905 mg/d 
45 months Moderate or 
high 
Italy
GISSI-P 1999 28 n3 EPA+DHA vs 
nil 
People with recent MI
 
5666 intervention, 
5658 control 
Supplement (capsule), 850-882 mg/d 
EPA + DHA daily, ratio 1:2 
42 months Moderate or 
high 
Italy
GLAMT 1993  29 n6 GLA vs non-
fat 
People with mild diabetic 
neuropathy 
54 intervention, 
57 control 
Supplement (capsule), 0.48g/d GLA 12 months Moderate or 
high 
UK and 
Finland 
HARP- Sacks 1995 
30   
n3 EPA+DHA vs 
MUFA 
Patients with coronary 
heart disease 
41 intervention, 
39 control 
Supplement (capsule), 6g/d LCn3 24 months Moderate or 
high 
USA
Higashihara 2010 31 n3 EPA vs nil **Prostate cancer 
patients with PSA levels 
<0.2 ng/ml 3 months 
after prostatectomy 
34 intervention, 
34 control 
Supplement (capsule), 2.4 g/d EPA 24 months Moderate or 
high 
Japan 
Huang 1996 32 n3 EPA+DHA vs 
n6 LA 
**People with Dukes A or 
B adenocarcinoma of 
colon or rectum or 
severely dysplastic 
17 intervention, 
10 control 
Supplement (capsules), 4g/d EPA + 
2g/d DHA 
12 months Moderate or 
high 
USA
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adenomatoid polyps 
post-surgery 
JELIS 2007 33   n3 EPA vs nil People with 
hypercholesterolaemia 
 
9326 intervention, 
9319 control 
Supplement (capsule), 1.8g/d EPA 60 months Moderate or 
high 
Japan
Ley 2004 34, 35 Higher vs lower 
PUFA (inverted) 
Adults with impaired 
glucose intolerance or 
high normal blood 
glucose 
85 intervention, 
90 control 
Diet advice, aim reduced fat diet (no 
specific goal stated), which reduced 
PUFA 
12 months Low (dietary 
advice trial) 
New 
Zealand 
Macsai 2008 36 n3 ALA vs MUFA People with meibomian
gland dysfunction 
18 ALA 
intervention, 20 
control 
Supplement (capsules), 3.3g/d ALA, 
1.14g/d LA 
12 months Moderate to 
high 
USA
Mansel 1990 37-39 n6 GLA vs non-
fat 
Women with 
macroscopic breast cysts 
100 intervention, 
100 control 
Supplement (capsules), estimated at 
0.54g/d GLA 
12 months Moderate or 
high 
UK
McIllmurray 1987 
40 
n6 GLA vs "inert 
placebo" 
**People within 1 month 
of operation to remove 
Dukes's C colorectal 
cancer 
25 intervention, 
24 control 
Supplement (capsules), 3.0g/d GLA 40 months Moderate to 
high 
UK
Mita 2007 41 n3 EPA vs nil Japanese type 2 diabetics 40 intervention, 
41 control 
Supplement (capsules), 1.8g/d 
EPA+DHA 
24 months Moderate or 
high 
Japan
MRC 1968 42-44 n6 LA vs mixed 
fats, also higher 
vs lower PUFA 
Men who have survived a 
MI 
199 intervention, 
194 control 
Diet advice plus oil supplement, 
reduce dietary fat to 35g/d fat, add 
84g/d soya oil 
48 months Moderate or 
high 
UK
NDHS Open 1st 
1968 43, 45 
n6 LA vs mixed 
fats, also higher 
vs lower PUFA 
Free-living men aged 45-
54 years 
829 combined 
intervention 
groups, 382 
control 
Diet provided (bought from a trial 
shop), saturated fats replaced in 
shop foods by polyunsaturated fats 
and oils 
12 months Low USA
OFAMI - Nilsen 
2001 46 
n3 EPA+DHA vs 
n6 LA 
Patients recruited 4-8 
days after MI 
150 intervention, 
150 control 
Supplement (capsules), 3.5g/d 
EPA+DHA 
24 months Moderate or 
high 
Norway 
OMEGA 2009 47, 48 n3 EPA+DHA vs 
MUFA 
People who have had an 
acute MI 
1940 intervention, 
1911 control 
supplement (capsules), 460mg/d 
EPA and 386mg/d DHA 
12 months Low Germany 
ORIGIN 2013 49-51 n3 EPA+DHA vs 
MUFA 
People at high risk of CVD 
with impaired fasting 
glucose, impaired glucose 
tolerance or DM 
6319 intervention, 
6292 control 
supplement (capsule), (465mgEPA + 
375mgDHA) EPA+DHA 0.84g/d 
72 months Low 40 locations 
in Europe 
and the 
Americas 
ORL Tatsuno 2013 
52, 53 
n3 EPA+DHA high 
dose vs low dose 
vs n3 EPA 
Japanese adults with 
hypertriglyceridaemia 
171 intervention 
(4g TAK), 165 
control (2g TAK) 
Supplement (capsules), 1.68g/d 
EPA+DHA 
12 months Moderate or 
high 
Japan
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PREDIMED 2013 54, 
55 
PUFA vs MUFA People free of CVD but 
with DM or at least 3 CVD 
risk factors 
2454 Med with 
nuts, 2543 Med 
with olive oil 
Dietary advice and food supplement, 
Mediterranean dietary advice (both 
groups) plus 30g/d mixed nuts  
60 months Moderate to 
high 
Spain
Puri 2005 56 n3 EPA vs non-fat People with Huntington's 
Disease 
67 intervention, 
68 control 
Supplement (capsule), 1.9g/d 
EPA+DHA 
12 months Low UK, USA, 
Canada, 
Australia 
Raitt 2005 57  n3 EPA+DHA vs 
MUFA 
People with implantable 
cardioverter defibrillators 
and recent sustained 
ventricular tachycardia or 
ventricular fibrillation 
100 intervention, 
100 control 
Supplement (capsules), 0.76g/d EPA, 
0.54g/d DHA (EPA+DHA 1.3g/d) 
24 months Moderate or 
high 
USA
Risk & Prevention 
2013 58, 59 
n3 EPA+DHA vs 
MUFA 
Patients with multiple 
cardiovascular risk factors 
6244 intervention, 
6269 control 
Supplement (capsules), 0.86g/d 
EPA+DHA 
60 months Moderate or 
high 
Italy
Rossing 1996 60, 61 n3 EPA+DHA vs 
MUFA 
Adults with insulin-
dependent DM mellitus, 
diabetic nephropathy & 
normal BP 
18 intervention, 
18 control 
Supplement (capsule), 2g/d EPA, 
2.6g/d DHA, 4.6g/d EPA+DHA 
12 months Moderate or 
high 
Denmark 
Sandhu 2016  62, 63 n3 EPA+DHA vs 
nil, +/- raloxifene 
*Healthy 
postmenopausal women 
with high breast density 
detected on routine 
mammogram screening 
54 & 53 
intervention, 53 & 
53 control 
Supplement (capsules), 1.86g/d EPA, 
1.5 g/d DHA 
24 months Moderate or 
high 
USA 
SCIMO - von 
Schacky 1999 64-66 
n3 EPA+DHA vs 
mixed fats 
People with 
angiographically proven 
coronary artery disease 
112 intervention, 
111 control 
Supplement (capsule), 1.03g/d 
EPA+DHA 
24 months Low Germany 
seAFOod Hull 2018 
67 
n3 EPA vs MCT *Bowel cancer screening 
patients  identified as 
"high risk" at their 1st 
colonoscopy 
356 intervention, 
353 control 
supplement (capsule), 2g/d EPA 12 months Low UK
Simon 1997  68 Higher vs lower 
PUFA (inverted) 
*Women with a high risk 
of breast cancer 
98 intervention, 
96 control 
Dietary advice, reduced fat including 
PUFA vs usual diet 
24 months Moderate or 
high 
USA
SOFA 2006 69-72 n3 EPA+DHA vs 
n6 LA 
People with previous 
ventricular arrhythmias & 
implantable cardioverter 
defibrillators 
273 intervention, 
273 control 
supplement (capsule), 464mg/d EPA 
+ 335mg/d DHA and 162mg/d other 
n-3 PUFA, EPA+DHA 0.8g/d 
 
12 months Low 8 countries 
in Europe 
SU.FOL.OM3 Galan 
2010 73-78 
n3 EPA+DHA vs 
non-fat 
People with a history of 
MI, unstable angina or 
ischemic stroke 
1253 intervention, 
1248 control 
supplement (capsule), 400mg/d EPA 
and 200mg/d DHA, EPA+DHA 0.6g/d 
48 months Low France
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THIS DIET 2008 79 n3 EPA+DHA vs 
nil 
Recent survivors of first 
MI 
51 intervention, 
50 control 
Dietary advice, Mediterranean style 
diet high in n3 (>0.75%E from n3, 
unclear how much EPA, DHA, ALA) 
24 months Moderate or 
high 
USA
Veterans Admin 
1969 43, 80, 81 
n6 LA vs SFA, also 
higher vs lower 
PUFA 
Men living at the 
Veterans Administration 
Centre 
424 intervention, 
422 control 
diet provided (residential 
institution), total fat 40%E, 2/3 of 
SFA replaced by unsaturated fats 
(from corn, soybean, safflower and 
cottonseed oils) 
Up to 96 months Moderate or 
high 
USA
VITAL 2018 82 n3 EPA & DHA vs 
MUFA 
Multi-ethnic population 
of > 25,000 apparently 
healthy adults without 
cancer or CVD 
12933 
intervention, 
12938 control 
Supplement (capsules), 465 mg/d 
EPA, 375 mg/d DHA (EPA + DHA 
840mg/d) 
median 5.3 
years 
Low USA
WAHA 2016  83-85 n3 ALA vs unclear Middle aged healthy 
adults 
362 intervention, 
346 control 
Supplement (food), usual diet & 
walnuts (15%E, ~5g/d ALA) vs usual 
diet 
24 months Moderate to 
high 
Spain & USA 
WINS 2006 86-88 Higher vs lower 
PUFA (inverted) 
**Women with localised 
resected breast cancer 
975 intervention, 
1462 control 
dietary advice, reduced fat intake 
(with reduced PUFA) 
60 months Low (as diet 
advice trial) 
USA
   
Summary:  
47 trials,  
49 comparisons 
34 LCn3 
3 ALA 
8 n6  
9 total PUFA 
38 Normal cancer risk
3 *Cancer risk factors 
6 **Previous cancer 
97,548 LCn3
  3,179 ALA 
  4,976 n6 
11,573 tot PUFA 
Total: 108,194 
Mean 30.4 
months 
17 trials at 
Low 
summary risk 
of bias 
15 N 
America 
20 Europe  
2 
Australia/NZ 
5 Japan 
5 combined 
  
Footnotes 
ALA = alpha-linolenic acid, BP = blood pressure, CVD = cardiovascular disease, DHA = docosahexaenoic acid, DM = diabetes mellitus, DPA = docosapentaenoic acid, E = 
energy intake, EPA = eicosapentaenoic acid or icosapentaenoic acid, LCn3 = long-chain omega-3, MI = myocardial infarction, MUFA = mono-unsaturated fatty acids, n3 = 
omega 3, PUFA = polyunsaturated fatty acids, SFA = saturated fatty acids, TG = serum triglycerides.  
Colour coding: LCn3  uncoloured, ALA blue, n6 yellow,  total PUFA red, N6 and PUFA pink. 
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Supplementary Table 2. High vs low LCn3 (primary outcomes)   
Outcome Sensitivity Analysis (SA) or Subgroup Studies Participants Statistical Method Effect Estimate I2, 
%
p-
value* 
 
All cancer 
diagnoses 
Main  27 113557 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.07] 0 - 
SA Fixed effects 27 113557 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.98, 1.07] 0 - 
SA Low summary risk of bias 12 66335 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.06] 0 - 
SA compliance 12 34827 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.96, 1.10] 0 - 
SA n>100 25 113440 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.07] 0 - 
Duration: 12 to <24 months duration 9 6464 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.91, 1.15] 0 0.96 
Duration: 24 to <48 months duration 10 15144 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.91, 1.21] 0 
Duration: 48+ months duration 8 91949 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.97, 1.07] 0 
Dose: ≤400mg/d LCn3 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 0.93 
Dose: >400 to ≤1400mg/d LCn3 14 91676 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.07] 0 
Dose: >1400 to ≤2400mg/d LCn3 7 20599 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.93, 1.14] 0 
Dose: >2400mg/d to ≤4400mg/d LCn3 2 738 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.10, 9.52] 0 
Dose: >4400mg/d LCn3 2 238 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.64, 3.10] 0 
Dose: dose unclear 2 306 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.75, 1.23] 0 
LCn3 replacing MUFA 7 70432 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.97, 1.07] 0 0.23 
LCn3 replacing omega-6 3 1317 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.29, 1.17] 0 
LCn3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing other or unclear 17 41808 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.97, 1.13] 0 
Intervention: dietary advice 1 101 Risk Ratio (M-H, Random, 95% CI) 2.94 [0.12, 70.56] - 0.80 
Intervention: supplementary capsules 23 111016 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.07] 0 
Intervention: supplemental foods 1 202 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.59, 3.02] - 
Intervention: all foods provided 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Intervention: combination 2 2238 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.80, 1.50] 61
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Baseline cancer risk: low - usual 
population 
24 112499 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.98, 1.08] 0 0.81 
Baseline cancer risk: moderate - CA risk 
factors 
2 853 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.43, 1.96] 11
Baseline cancer risk: high - previous CA 1 205 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.75, 1.22] - 
Mean age <50 years 6 1346 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.29, 3.75] 0 0.95 
Mean age 50 to <65 years 17 80934 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.98, 1.08] 0 
Mean age 65+ years 4 31277 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.95, 1.09] 0 
Men & women mixed 24 110748 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.98, 1.07] 0 0.54 
Men only 2 2596 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.35, 2.19] 77
Women only 1 213 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.08] - 
        
Cancer 
deaths 
Main 18 99336 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.06] 0 - 
SA fixed effects 18 99336 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.90, 1.05] 0 - 
SA Low summary risk of bias 6 61433 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.86, 1.04] 0 - 
SA compliance 7 34122 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.85, 1.18] 0 - 
SA n>100 16 99194 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.06] 0 - 
Duration: 12 to <24 months duration 2 742 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.10, 9.52] 0 0.88 
Duration: 24 to <48 months duration 9 26379 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.85, 1.20] 0 
Duration: 48+ months duration 7 72215 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.05] 0 
Dose: ≤400mg/d LCn3 1 4837 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.76, 1.53] - 0.70 
Dose: >400 to ≤1400mg/d LCn3 10 86135 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06] 0 
Dose: >1400 to ≤2400mg/d LCn3 2 7037 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.73, 1.23] 0 
Dose: >2400 to ≤4400mg/d LCn3 3 1042 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.29, 10.83] 0 
Dose: >4400mg/d LCn3 1 80 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.57] - 
Dose: unclear 1 205 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.65] -  
LCn3 replacing MUFA 7 78284 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.87, 1.04] 0 0.25 
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LCn3 replacing omega-6 3 1071 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.28, 1.56] 0 
LCn3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing other or unclear 8 19981 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.91, 1.41] 0 
Intervention: dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 0.76 
Intervention: supplementary capsules 14 89147 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.88, 1.05] 0 
Intervention: supplemental foods 1 4837 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.76, 1.53] - 
Intervention: all foods provided 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Intervention: combination 3 5352 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.67, 1.68] 6 
Baseline cancer risk: low - usual 
population 
16 99069 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.06] 0 0.15 
Baseline cancer risk:  moderate - CA risk 
factors 
0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Baseline cancer risk: high - previous CA 2 267 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.75] 0 
Mean age <50 3 950 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.11, 4.33] 0 0.93 
Mean age 50-<65 11 60140 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.08] 2 
Mean age 65+ 4 38246 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.84, 1.12] 0 
Men & women mixed 14 93564 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06] 0 0.92 
Men only 4 5772 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.70, 1.40] 0 
Women only 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
        
 
 
Breast cancer 
diagnoses 
Main 12 44295 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.89, 1.20] 0 - 
SA fixed effects 12 44295 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.89, 1.20] 0 - 
SA Low summary risk of bias 7 26371 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.87, 1.22] 0 - 
SA compliance 6 13908 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.72, 1.30] 1 - 
SA n >100 11 44285 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.88, 1.20] 0 - 
Duration: 12 to <24 months duration 2 107 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.33, 25.76] 0 0.41 
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Duration: 24 to <48 months duration 2 313 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.05, 2.94] 0 
Duration: 48+ months duration 8 43875 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.89, 1.20] 0 
Dose: ≤400mg/d LCn3 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 0.60 
Dose: >400 to ≤1400mg/d LCn3 7 31089 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.90, 1.23] 0 
Dose: >1400 to ≤2400mg/d LCn3 3 13096 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.41, 1.42] 0 
Dose: >2400 to ≤4400mg/d LCn3 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Dose: >4400mg/d LCn3 2 110 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.18, 10.01] 0 
Dose: unclear 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing MUFA 5 28095 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.89, 1.23] 0 0.71 
LCn3 replacing omega-6 1 102 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.85] - 
LCn3 replacing SFA 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
LCn3 replacing other or unclear 6 16098 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.63, 1.54] 5 
Intervention: dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 0.76 
Intervention: supplementary capsules 11 44195 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.89, 1.20] 0 
Intervention: supplemental foods 1 100 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.04, 10.35] - 
Intervention: all foods provided 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Baseline cancer risk: low - usual 
population 
11 44082 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.89, 1.20] 0 0.28 
Baseline cancer risk: moderate - CA risk 
factors 
1 213 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.08] - 
Baseline cancer risk: high - previous CA 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Mean age <50 2 112 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.10, 9.88] 11 0.43 
Mean age 50-<65 8 28710 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.92, 1.38] 0 
Mean age 65+ 2 15473 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.16] 0 
Men & women mixed 11 44082 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.89, 1.20] 0 0.28 
Men only 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
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Women only 1 213 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.08] - 
        
 
Breast cancer 
deaths 
Main 2 3216 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.09, 8.96] 3 - 
SA fixed effects 2 3216 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.13, 6.26] 3 - 
SA low summary RoB 1 102 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.85] - - 
SA compliance 1 102 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.01, 6.85] - - 
SA n >100 2 3216 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.09, 8.96] 3 - 
        
 
Prostate 
cancer 
diagnoses 
Main 7 38525 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.97, 1.24] 0 - 
SA fixed effects 7 38525 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.24] 0 - 
SA Low summary risk of bias 6 36492 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.98, 1.25] 0 - 
SA compliance 4 18658 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.99, 1.39] 0 - 
SA n >100 7 38525 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.97, 1.24] 0 - 
        
 
Prostate 
cancer deaths 
Main 2 5101 Risk Ratio (M-H, Random, 95% CI) 2.82 [0.43, 18.54] 0 - 
SA fixed effects 2 5101 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [0.47, 18.89] 0 - 
SA low summary risk of bias 1 1987 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.18, 22.00] - - 
SA compliance 1 1987 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.18, 22.00] - - 
SA  n >100 2 5101 Risk Ratio (M-H, Random, 95% CI) 2.82 [0.43, 18.54] 0 - 
        
Dichotomous 
markers of 
cancer risk 
PSA >2ng/ml twice at consecutive 
measurements 
1 62 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.16, 1.40] - - 
        
Continuous 
markers of 
cancer risk 
Breast density LCn3, cm2  1 175 Mean Difference (IV, Random, 95% 
CI) 
2.06 [-4.68, 8.81] - - 
PSA, ng/ml 1 1622 Mean Difference (IV, Random, 95% 
CI) 
-0.13 [-0.25, -0.01] - - 
* test for subgroup differences, p-value 
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Supplementary Table 3. High vs low LCn3 (secondary outcomes)   
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, %
Quality of 
life 
- 0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
Adiposity, 
Weight or 
BMI 
Weight, kg 3 14913 Mean Difference (IV, Random, 95% CI) 0.42 [-0.87, 1.71] 63 
BMI, kg/m2 4 14268 Mean Difference (IV, Random, 95% CI) 0.06 [-0.08, 0.19] 0 
Waist circumference, cm 1 71 Mean Difference (IV, Random, 95% CI) -1.40 [-7.94, 5.14] - 
 
Side 
effects 
Drop outs due to side effects 13 12324 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.98, 1.76] 19 
Abdominal pain or discomfort 5 13655 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.93, 1.47] 9 
Diarrhoea 7 1869 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.90, 1.48] 11 
Nausea 6 1296 Risk Ratio (M-H, Random, 95% CI) 1.75 [1.25, 2.47] 0 
Any gastrointestinal side effect 14 60282 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.89, 1.39] 84 
Bleeding 6 44641 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.70, 1.70] 59 
Skin problems (itching, rashes) 6 36032 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.44, 2.26] 75 
Headache or worsening migraine 3 996 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.48, 1.36] 0 
Psychiatric disorders 2 940 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.32, 1.54] 0 
All side effects combined 9 37656 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.93, 1.15] 85 
Drop outs  15 24461 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.10] 33 
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Supplementary Table 4. GRADE table: summary of findings of effects of omega-3 fats (LCn3 and ALA) on cancers 
 
High compared to low omega 3 (LCn3 and ALA) for cancers 
Patient or population: adults, Setting: community, Intervention: Higher omega-3 intake, Comparison: lower omega-3 intake
Outcomes 
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments Risk with low omega 3 
(primary outcomes) 
Risk with High
Cancer diagnoses - LCn3  64 per 1,000  65 per 1,000 (63 to 68)  
RR 1.02 
(0.98 to 1.07)  
113557 
(27 RCTs)  
⨁⨁⨁⨁ 
HIGH  
Increasing LCn3 has little or no effect on risk of diagnosis of 
any cancer.  
Cancer deaths - LCn3  23 per 1,000  
23 per 1,000 
(21 to 25)  
RR 0.97 
(0.90 to 1.06)  
99336 
(18 RCTs)  
⨁⨁⨁◯ 
MODERATE a 
Increasing LCn3 probably has little or no effect on risk of 
cancer death.  
Breast cancer diagnoses - LCn3  15 per 1,000  
15 per 1,000 
(13 to 18)  
RR 1.03 
(0.89 to 1.20)  
44295 
(12 RCTs)  
⨁⨁⨁◯ 
MODERATE b,c 
Increasing LCn3 probably has little or no effect on risk of 
breast cancer diagnosis.  
Breast cancer deaths - LCn3  1 per 1,000  
1 per 1,000 
(0 to 6)  
RR 0.91 
(0.09 to 8.96)  
3216 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW d,e 
The effect of increasing LCn3 on breast cancer deaths is 
unclear as the evidence is of very low quality.  
Prostate cancer diagnoses - LCn3  25 per 1,000  
28 per 1,000 
(24 to 31)  
RR 1.10 
(0.97 to 1.24)  
38525 
(7 RCTs)  
⨁⨁◯◯ 
LOW f,g 
Increasing LCn3 may increase the risk of prostate cancer.  
Prostate cancer deaths - LCn3  0 per 1,000  
1 per 1,000 
(0 to 7)  
RR 2.82 
(0.43 to 18.54)  
5101 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW e,f 
The effect of increasing LCn3 on prostate cancer death is 
unclear as the evidence is of very low quality.  
Cancer diagnoses - ALA  22 per 1,000  
21 per 1,000 
(8 to 55)  
RR 0.98 
(0.38 to 2.55)  
752 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW e,h 
The effect of increasing ALA on diagnosis of any cancer is 
unclear as the evidence was of very low quality.  
Cancer deaths - ALA  22 per 1,000  
23 per 1,000 
(16 to 32)  
RR 1.05 
(0.74 to 1.49)  
5545 
(2 RCTs)  
⨁⨁⨁◯ 
MODERATE c 
Increasing ALA probably has little or no effect on risk of 
cancer death.  
Breast cancer diagnoses - ALA  8 per 1,000  
9 per 1,000 
(1 to 58)  
RR 1.11 
(0.17 to 7.40)  
513 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW e,h 
The effect of increasing ALA on risk of breast cancer 
diagnosis is unclear as the evidence is of very low quality.  
Breast cancer deaths - ALA  not pooled  not pooled not pooled  (0 RCTs)  -  We found no evidence to address this issue.  
Prostate cancer diagnoses - ALA  10 per 1,000  
13 per 1,000 
(7 to 23)  
RR 1.30 
(0.72 to 2.32)  
4010 
(2 RCTs)  
⨁⨁◯◯ 
LOW i,j 
Increasing ALA may increase the risk of prostate cancer 
diagnosis.  
Prostate cancer deaths - ALA  not pooled  not pooled not pooled  (0 RCTs)  -  No evidence found  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio  
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High compared to low omega 3 (LCn3 and ALA) for cancers 
Patient or population: adults, Setting: community, Intervention: Higher omega-3 intake, Comparison: lower omega-3 intake
Outcomes 
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments Risk with low omega 3 
(primary outcomes) 
Risk with High
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Imprecision: 95% CI included a small reduction in risk as well as little or no effect. Downgraded once.  
b. Inconsistency: data were consistent across all sensitivity analyses, including limiting analysis to only trials at low summary risk of bias, and consistent with the suggestion of little or no effect for breast density. Not downgraded.  
c. Imprecision: 95% CI included both increases and reductions in risk. Downgraded once.  
d. Risk of bias: sensitivity analysis retaining only trials at low summary risk of bias altered apparent effect. Downgraded once.  
e. Imprecision: 95% CI included both important benefit and important harm. Downgraded twice.  
f. Inconsistency: While data on prostate cancer diagnosis and deaths across sensitivity analyses are consistent in suggesting that increasing LCn3 increases prostate cancer risk, including limiting to trials at low summary risk of bias, PSA 
data suggest that LCn3 reduces PSA (which would tend to protect against prostate cancer). Downgraded once.  
g. Imprecision: 95% CI included no effect as well as harm. Downgraded once.  
h. Risk of bias: Neither included trial was at low summary risk of bias. Downgraded once.  
i. Inconsistency: consistent across all sensitivity analyses, including when limiting only to trials at low summary risk of bias, and consistent with PSA data. Not downgraded.  
j. Imprecision: 95% CI included benefits as well as harms. Downgraded twice.  
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Supplementary Table 5. High vs low ALA (primary outcomes)   
 
Outcome Sensitivity Analysis (SA) or 
Subgroup
Studies Participants Statistical Method Effect Estimate I2, %
 
All cancer diagnoses 
Main  2 752 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.38, 2.55] 0 
SA Fixed effects  2 752 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.37, 2.46] 0 
SA Low summary risk of bias 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA compliance  1 708 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.40, 2.98] -
SA n>100 1 708 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.40, 2.98] - 
       
 
Deaths from any 
cancer 
Main 2 5545 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.74, 1.49] 0 
SA fixed effects 2 5545 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.75, 1.50] 0 
SA low summary risk of bias 1 4837 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.73, 1.48] - 
SA compliance 2 5545 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.74, 1.49] 0 
SA n>100   2 5545 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.74, 1.49] 0 
       
 
Breast cancer 
diagnoses 
Main  2 513 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.17, 7.40] 0 
SA fixed effects 2 513 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.18, 6.40] 0 
SA Low summary risk of bias 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA compliance 1 481 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.18, 
21.28] 
- 
SA n>100   1 481 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.18, 
21.28] 
- 
       
Breast cancer deaths Main  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
       
  Main  2 4010 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.72, 2.32] 0 
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Prostate cancer 
diagnoses 
SA fixed effects   2 4010 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.73, 2.34] 0 
SA Low summary risk of bias  1 3783 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.67, 2.24] 0 
SA compliance   2 4010 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.72, 2.32] 0 
SA n >100   2 4010 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.72, 2.32] 0 
       
Prostate cancer deaths Main  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
       
Dichotomous markers 
of cancer risk 
PSA >4ng/ml 1 1622 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.86, 1.50] - 
       
Continuous markers of 
cancer risk 
PSA, ng/ml 1 1622 Mean Difference (IV, Random, 95% 
CI) 
0.10 [-0.03, 0.23] - 
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Supplementary Table 6. High vs low ALA (secondary outcomes)   
 
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, %
Quality of life - 0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
       
Adiposity  Weight, kg, ALA 0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
  BMI, kg/m2, ALA 1 1260 Mean Difference (IV, Random, 95% CI) 0.15 [-0.03, 0.33] - 
       
Side effects  Drop outs due to side effects 1 2433 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.47, 1.65] - 
  Any gastrointestinal side effect 1 2433 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.38, 2.28] - 
Dropouts  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
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Supplementary Table 7. High vs low omega-6 (primary outcomes)   
 
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, % 
  
Cancer diagnoses 
Main 6 4272 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.96, 1.53] 0 
dietary advice & supplemental foods 4 3961 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.80, 1.70] 35 
GLA supplement 2 311 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.31, 5.98] 0 
SA fixed effects 6 4272 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.95, 1.51] 0 
SA low summary RoB 1 689 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.99] - 
SA compliance 4 3961 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.80, 1.70] 35 
SA n >100 6 4272 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.96, 1.53] 0 
       
 
Cancer deaths 
Main 4 3321 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.51, 1.85] 52 
SA fixed effects 4 3321 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.77, 1.64] 52 
SA low summary RoB 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA compliance 3 3272 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.33, 2.66] 58 
SA  n >100 3 3272 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.33, 2.66] 58 
       
 
Breast cancer 
diagnoses 
Main 1 200 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.14, 6.96] - 
SA fixed effects 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 6.96] - 
SA low summary RoB 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA compliance 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA  n >100 1 200 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.14, 6.96] - 
       
Breast cancer deaths Main  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
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Prostate cancer 
diagnoses 
Main 1 2033 Risk Ratio (M-H, Random, 95% CI) 2.24 [0.69, 7.26] - 
SA fixed effects 1 2033 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [0.69, 7.26] - 
SA low summary RoB 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
SA compliance 1 2033 Risk Ratio (M-H, Random, 95% CI) 2.24 [0.69, 7.26] - 
SA  n >100 1 2033 Risk Ratio (M-H, Random, 95% CI) 2.24 [0.69, 7.26] - 
       
Prostate cancer 
deaths 
 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Dichotomous 
markers of cancer 
risk 
 0 0 Mean Difference (IV, Random, 95% 
CI) 
Not estimable - 
Continuous markers 
cancer risk 
Breast density 0 0 Mean Difference (IV, Random, 95% 
CI) 
Not estimable - 
PSA 0 0 Mean Difference (IV, Random, 95% 
CI) 
Not estimable - 
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Supplementary Table 8. High vs low omega-6 (secondary outcomes)   
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, % 
Quality of life  0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
Adiposity  Weight, kg 1 177 Mean Difference (IV, Random, 95% CI) Not estimable - 
  BMI, kg/m2 0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
Side effects  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Drop outs  2 311 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.40, 1.22] 0 
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Supplementary Table 9. GRADE table: summary of findings of effects of omega-6 fats on cancers 
 
High compared to low omega 6 for cancer outcomes 
Patient or population: adults, Setting: community, Intervention: Higher omega-6 intake, Comparison: low omega 6 intake
Outcomes 
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)  
№ of participants 
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments Risk with low omega 6 
(primary outcomes) 
Risk with High
Cancer diagnoses  56 per 1,000  
68 per 1,000 
(54 to 86)  
RR 1.21 
(0.96 to 1.53)  
4272 
(6 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
The effect of increasing omega-6 on cancer diagnosis is unclear as the 
evidence is of very low quality.  
Cancer deaths  26 per 1,000  
25 per 1,000 
(13 to 48)  
RR 0.97 
(0.51 to 1.85)  
3321 
(4 RCTs)  
⨁◯◯◯ 
VERY LOW c,d,e 
The effect of omega-6 on cancer deaths is unclear as the evidence is of 
very low quality.  
Breast cancer diagnoses  20 per 1,000  
20 per 1,000
(3 to 139)  
RR 1.00 
(0.14 to 6.96)  
200 
(1 RCT)  
⨁◯◯◯ 
VERY LOW c,f,g 
The effect of omega-6 on breast cancer diagnoses is unclear as the 
evidence is of very low quality.  
Breast cancer deaths  not pooled  not pooled not pooled  (0 RCTs)  -  We found no trials for this comparison  
Prostate cancer diagnosis  4 per 1,000  
9 per 1,000 
(3 to 29)  
RR 2.24 
(0.69 to 7.26)  
2033 
(1 RCT)  
⨁◯◯◯ 
VERY LOW c,e,f 
The effect of omega-6 on risk of prostate cancer diagnosis is unclear as 
the evidence is of very low quality.  
Prostate cancer death  0 per 1,000  0 per 1,000 (0 to 0)  not estimable  (0 RCTs)  -  We found no trials assessing this effect.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; MD: Mean difference  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Risk of bias: limiting analysis to trials at low summary risk of bias moves effect from harm to benefit (in the single remaining trial). Downgraded twice.  
b. Imprecision: 95% CI includes harm and also no effect. Downgraded once.  
c. Risk of bias: None of the included trials were at low summary risk of bias. Downgraded once.  
d. Inconsistency: I2 was >50% but less than 60%. Downgraded once.  
e. Imprecision: 95% CI includes both benefits and harms. Downgraded once.  
f. Indirectness: Only one trial assessed this outcome. Downgraded once.  
g. Imprecision: 95% includes both important benefits and harms. Downgraded twice.  
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Supplementary Table 10. High vs low total PUFA (primary outcomes)   
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, % p-
value*
 
Cancer 
diagnoses 
Main 8 9428 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.99, 1.42] 0 - 
SA fixed effects 8 9428 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.98, 1.41] 0 - 
 SA low summary risk of bias 3 3262 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.78, 1.51] 0 - 
SA by compliance 6 4230 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.94, 1.54] 5 - 
SA n >100 8 9428 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.99, 1.42] 0 - 
Duration: 1 to <2 years 2 825 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.06, 2.79] 0 0.54 
Duration: 2 to <4 years 2 2166 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.86, 1.53] 0 
Duration: 4+ years 4 6437 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.89, 1.69] 27 
Dose of PUFA: <0.5%E 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 0.89 
Dose of PUFA: 0.5 to <1.0%E 1 136 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.04, 5.08] - 
Dose of PUFA: 1.0 to <2.0%E 1 2437 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.80, 1.56] - 
Dose of PUFA: 2.0 to <5.0%E 2 2166 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.86, 1.53] 0 
Dose of PUFA: ≥5.0%E 3 1928 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.24, 2.64] 52 
Dose of PUFA: unclear 1 2761 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.57, 3.63] - 
PUFA replacing MUFA 1 2761 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.57, 3.63] - 0.50 
PUFA replacing mixed fats 3 3115 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.35, 1.85] 29 
PUFA replacing SFA 1 846 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.01, 2.20] - 
PUFA replacing CHO 3 2706 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.83, 1.53] 0 
Low risk - usual population 6 6858 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.93, 1.56] 7 0.80 
Moderate risk - CA risk factors 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
High risk - previous cancer 2 2570 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.84, 1.56] 0 
Mean age <50 years 1 689 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.99] - 0.27 
Mean age 50- <65 5 5132 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.89, 1.36] 0 
Mean age 65+ 2 3607 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.04, 2.12] 0 
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Men & women mixed 3 3030 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.71, 2.30] 0 0.92 
Men only 4 3961 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.80, 1.70] 35 
Women only 1 2437 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.80, 1.56] - 
        
 
Cancer 
deaths 
Main  4 3408 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.48, 2.49] 37 - 
SA fixed effects 4 3408 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.81, 1.99] 37 - 
SA low summary risk of bias 1 136 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.18, 
20.31] 
- - 
SA compliance 4 3408 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.48, 2.49] 37 - 
SA n >100 4 3408 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.48, 2.49] 37 - 
        
 
Breast cancer 
diagnoses 
Main  2 5198 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.71, 1.73] 0 - 
SA fixed effects 2 5198 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.71, 1.73] 0 - 
SA low summary risk of bias 1 2437 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.62, 1.71] - - 
SA compliance 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - - 
SA n >100 2 5198 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.71, 1.73] 0 - 
        
Breast cancer 
deaths 
Main  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - - 
        
 
Prostate 
cancer 
diagnoses 
Main  2 2879 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.80, 3.36] 0 - 
SA fixed effects 2 2879 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.82, 3.38] 0 - 
SA low summary risk of bias 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - - 
SA compliance 2 2879 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.80, 3.36] 0 - 
SA n >100 2 2879 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.80, 3.36] 0 - 
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Prostate 
cancer deaths 
Main  0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - - 
        
Dichotomous 
markers of 
cancer risk 
 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - - 
        
 
Continuous 
measures of 
cancer risk 
Breast density 0 0 Mean Difference (IV, Random, 95% 
CI) 
Not estimable - - 
PSA 0 0 Mean Difference (IV, Random, 95% 
CI) 
Not estimable - - 
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Supplementary Table 11. High vs low total PUFA (secondary outcomes)   
 
Outcome Sensitivity Analysis (SA) or 
Subgroup 
Studies Participants Statistical Method Effect Estimate I2, % 
Quality of 
life 
Main  0 0 Mean Difference (IV, Random, 95% CI) Not estimable - 
       
Adiposity Weight, kg 2 3800 Mean Difference (IV, Random, 95% CI) 0.37 [-0.05, 0.78] 0 
BMI, kg/m2 1 320 Mean Difference (IV, Random, 95% CI) 0.01 [-0.30, 0.31] 0 
Waist circumference, cm 1 331 Mean Difference (IV, Random, 95% CI) 0.31 [-0.80, 1.43] 0 
       
Side effects Drop outs due to side effects 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Bleeding 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable - 
Drop outs  0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable - 
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Supplementary Table 12. GRADE table: summary of findings of effects of total PUFA on cancers 
 
High compared to low total PUFA for cancers 
Patient or population: adults, Setting: community, Intervention: Higher total PUFA, Comparison: low total PUFA 
Outcomes 
Anticipated absolute effects* (95% CI)
Relative effect 
(95% CI)  
№ of participants  
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments Risk with low total PUFA 
(primary outcomes) 
Risk with High
Cancer diagnoses  41 per 1,000  
49 per 1,000 
(41 to 58)  
RR 1.19 
(0.99 to 1.42)  
9428 
(8 RCTs)  
⨁⨁◯◯ 
LOW a,b,c 
Increasing total PUFA may increase risk of diagnosis of any cancer.  
Cancer deaths  19 per 1,000  
21 per 1,000 
(9 to 47)  
RR 1.10 
(0.48 to 2.49)  
3408 
(4 RCTs)  
⨁⨁◯◯ 
LOW d 
Increasing total PUFA may increase the risk of cancer death.  
Breast cancer diagnoses  13 per 1,000  
14 per 1,000
(9 to 23)  
RR 1.11 
(0.71 to 1.73)  
5198 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW e,f 
The effect of increasing total PUFA on risk of breast cancer diagnosis 
is unclear as the evidence is of very low quality.  
Breast cancer deaths  not pooled  not pooled not pooled  (0 RCTs)  -  We found no trials assessing effects of total PUFA on breast cancer death.  
Prostate cancer diagnoses  8 per 1,000  
14 per 1,000 
(7 to 28)  
RR 1.64 
(0.80 to 3.36)  
2879 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW f,g 
The effect of increasing total PUFA on risk of prostate cancer 
diagnosis is unclear as the evidence is of very low quality.  
Prostate cancer deaths  not pooled  not pooled not pooled  (0 RCTs)  -  We found no trials assessing this outcome.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; MD: Mean difference  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Risk of bias: Limiting to the 3 trials at low summary risk of bias moved the RR into "no effect" (RR 1.08). Downgraded once.  
b. Imprecision: 95% CI includes no effect as well as harm. Downgraded once.  
c. Publication bias: funnel plot suggests that if missing small studies were added into the meta-analysis it would increase RR. Not downgraded.  
d. Imprecision: 95% CI includes important benefit as well as harm. Downgraded twice.  
e. Risk of bias: Limiting to the single trial at low summary risk of bias moved the RR into "no effect" (RR 1.03). Downgraded once.  
f. Imprecision: 95% CI includes important  benefits and harms. Downgraded twice.  
g. Risk of bias: no included trial was at low summary risk of bias. Downgraded once.  
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